Heart failure: a major management challenge with encouraging recent progress.

[1]  J. Marangou,et al.  Current attitudes on cardiac devices in heart failure: a review. , 2015, Clinical therapeutics.

[2]  P. Macdonald,et al.  Latest developments in heart transplantation: a review. , 2015, Clinical therapeutics.

[3]  D. Kaye,et al.  Management of heart failure with preserved ejection fraction: a review. , 2015, Clinical therapeutics.

[4]  P. Macdonald.  Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. , 2015, Clinical therapeutics.

[5]  P. Davidson,et al.  Multidisciplinary management of chronic heart failure: principles and future trends. , 2015, Clinical therapeutics.

[6]  A. Markowitz,et al.  Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta‐analysis , 2015, Journal of cardiac surgery.

[7]  J. McMurray,et al.  Meta-Analysis of Large-Scale Randomized Trials to Determine the Effectiveness of Inhibition of the Renin-Angiotensin Aldosterone System in Heart Failure. , 2015, The American journal of cardiology.

[8]  E. Braunwald.  The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. , 2015, Journal of the American College of Cardiology.

[9]  E. Braunwald.  The war against heart failure: the Lancet lecture , 2015, The Lancet.

[10]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[11]  M. Jessup.  Neprilysin inhibition--a novel therapy for heart failure. , 2014, The New England journal of medicine.

[12]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[13]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[14]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[15]  K. Glas,et al.  A review of cardiac transplantation. , 2013, Anesthesiology clinics.

[16]  S. Solomon,et al.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. , 2013, JAMA.

[17]  D. Mukherjee,et al.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis , 2013, The BMJ.

[18]  B. V. Van Tassell,et al.  Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis , 2013, BMJ.

[19]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[20]  Juerg Schwitter,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[21]  K. Dickstein,et al.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE , 2012, European journal of heart failure.

[22]  J. McMurray.  CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure , 2011, European journal of heart failure.

[23]  J. Cleland,et al.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.

[24]  A. Clark,et al.  A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions , 2011, Trials.

[25]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[26]  Henry Krum,et al.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study , 2011, European journal of heart failure.

[27]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[28]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[29]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[30]  R. McKelvie,et al.  Angiotensin receptor blockers for heart failure. , 2001, The Cochrane database of systematic reviews.